PLAT and Stroke: This strongly suggests that, in conditions of ischemic brain injury, in which the integrity of the BBB is altered [30-32], the GluN2D-containing NMDAR antagonist UBP145, could be used as an adjunct therapy to increase the therapeutic window of tPA-mediated thrombolysis that today, is restricted to the first 4.5h after stroke onset [42].